ABSTRACT
OBJECTIVES: This project aims to develop a bio-natural nano-product with Cosmeceutical and pharmaceutical applications. METHODS: E. sativa oil was evaluated for its anti-oxidant, sun protection factor and elastase inhibition. Then, nanoemulgel formulations were prepared for E. sativa oil through the combination of nanoemulsion with hydrogel. E. sativa nanoemulsion formulations were prepared by the help of a selfemulsification technique. After this, the optimum formulation was mixed with Carbopol to produce the nanoemulgel. Anti-bacterial and anti-fungal activities were evaluated. RESULTS: Nanoemulsion occurred when the size of the droplets was 195.29 nm with the lowest polydispersibility index 0.207. The results of antioxidant, anti-elastase and SPF activities for E. sativa oil were 2.10 µg/ml, 25.1 µg/ml and an SPF value of 5.57, respectively. In addition, in the anti-bacterial test for Staphylococcus aureus, it was found that nanoemulgel has an inhibition zone of 2.1 cm in diameter. According to the MRSA, the inhibition zone was 1.5 cm. CONCLUSION: E. Sativa oil could be a promising candidate in cosmeceutical and pharmaceutical preparations.
Subject(s)
Anti-Infective Agents/pharmacology , Antioxidants/pharmacology , Brassicaceae/chemistry , Nanostructures/chemistry , Pancreatic Elastase/antagonists & inhibitors , Plant Oils/isolation & purification , Sun Protection Factor , Animals , Anti-Infective Agents/isolation & purification , Antioxidants/isolation & purification , Biphenyl Compounds/chemistry , Candida/drug effects , Drug Compounding , Emulsions , Gram-Negative Bacteria/drug effects , Gram-Positive Bacteria/drug effects , Hydrogels/chemistry , Picrates/chemistry , Seeds/chemistry , Skin/drug effects , Skin/enzymology , SwineABSTRACT
In order to develop a self-nanoemulsifying system, three components, olive oil, Tween 80, and Capmul, were used to construct a ternary phase diagram that helped to find the optimum formulation, which was loaded with nifedipine. The effect of sonication on drug loading was also evaluated. After that, measurement of the droplet size, size distribution, zeta potential, and scanning electron microscopy were conducted for evaluation and characterisation of the formulations. The phase diagram of four formulations showed nanosizes below 200 nm; however, only one was selected to be loaded with nifedipine. The selected formulation had the lowest droplet size of 98 nm and size distribution 0.192, and was composed of 48% Tween 80, 32% Capmul, and 20% olive oil. The nifedipine self-nanoemulsifying drug delivery system (SNEDDS) showed a significant change in the particle size (97 nm) and size distribution (0.257) after sonication. Its zeta potential was -32.3 mV indicating good stability. The SEM photographs of nifedipine showed particles with spherical shape and smooth surface. Finally, a self-nanoemulsifying formulation containing nifedipine, loaded in olive oil, was successfully prepared by mixing the oil with various types of surfactants and co-surfactants. A significant nifedipine self-nanoemulsifying system was developed and significantly improved accordingly.
ABSTRACT
BACKGROUND AND AIM: Reduced renal function requires dose adjustment for certain drugs to avoid toxicity. The aim of this study was to determine whether appropriate dosage adjustments were made for drugs that are nephrotoxic, excreted, or metabolized (TEM medications) by the kidney in patients with renal impairment. METHODOLOGY: A cross-sectional study of a group of hospitalized patients was carried out at Al-Watni governmental hospital, Nablus, Palestine. All patients with creatinine clearance
Subject(s)
Medication Errors , Pharmaceutical Preparations/administration & dosage , Renal Insufficiency/drug therapy , Adult , Aged , Aged, 80 and over , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/adverse effects , Anti-Bacterial Agents/pharmacokinetics , Creatinine/blood , Creatinine/urine , Cross-Sectional Studies , Digoxin/administration & dosage , Digoxin/adverse effects , Digoxin/pharmacokinetics , Drug-Related Side Effects and Adverse Reactions , Female , Hospital Bed Capacity, 100 to 299 , Hospitals, Public , Humans , Israel , Male , Middle Aged , Models, Statistical , Pharmacokinetics , Ranitidine/administration & dosage , Ranitidine/adverse effects , Ranitidine/pharmacokinetics , Renal Insufficiency/physiopathologySubject(s)
Adrenergic beta-Antagonists/therapeutic use , Angiotensin-Converting Enzyme Inhibitors/therapeutic use , Myocardial Infarction/diagnostic imaging , Myocardial Infarction/drug therapy , Aged , Cohort Studies , Coronary Angiography , Drug Utilization , Female , Follow-Up Studies , Humans , Intensive Care Units , Male , Middle Aged , Myocardial Infarction/mortality , Practice Patterns, Physicians' , Registries , Risk Assessment , Severity of Illness Index , Survival Rate , Treatment OutcomeABSTRACT
OBJECTIVE: To investigate the frequency of potential antihypertensive drug interactions among patients with cardiovascular diseases receiving antihypertensive medications. METHODS: The study took place in Nablus, Palestine starting April through October 2003. Patients with cardiovascular diseases (n=876) or who were receiving one or more antihypertensive medications were evaluated. All drugs prescribed for the patients were obtained from their medical files. A drug interaction database was developed based on updated Drug Interaction Facts to examine potential and level of drug interactions in each patient's regimen. Data were entered and analyzed using SPSS software. RESULTS: The number of "unique" pairs of potential drug interactions among the antihypertensive agents present in the data was 433. These included 16 cases (3.7%) level one; 34 cases (7.8%) level 2; 116 cases (26.8%) level 3; 136 cases (31.4%) level 4, and 131 (30.3%) level 5 interactions. Both increasing age and number of drugs were significantly associated with the potential for significant interactions at all levels with a p value less than 0.025. CONCLUSIONS: This study found a high frequency of potential drug interactions with agents typically used for hypertension. Similar investigations need to be carried out among patients with other types of chronic diseases. Drug interaction software might be necessary in governmental pharmacy departments.
